Autologous CAR-T cell therapy
Showing 1 - 25 of >10,000
Multiple Myeloma, Refractory, Multiple Myeloma in Relapse Trial in Cleveland (Autologous CAR-T cell therapy expressing the
Not yet recruiting
- Multiple Myeloma, Refractory
- Multiple Myeloma in Relapse
- Autologous CAR-T cell therapy expressing the BAFF-ligand.
-
Cleveland, OhioUniversity Hospitals Seidman Cancer Center
Jan 11, 2023
Neuroendocrine Tumor (NET), Colorectal Cancer (CRC) Trial (CHM-2101 CAR-T cells)
Not yet recruiting
- Neuroendocrine Tumor (NET)
- Colorectal Cancer (CRC)
- CHM-2101 CAR-T cells
- (no location specified)
Sep 20, 2023
Hematologic Malignancy, Large B-cell Lymphoma, Acute Lymphoblastic Leukemia Trial in Los Angeles (autologous hematopoietic stem
Not yet recruiting
- Hematologic Malignancy
- +5 more
- autologous hematopoietic stem cells added to planned CAR T
-
Los Angeles, CaliforniaCedars-Sinai Medical Center
May 31, 2023
Recurrent Glioblastoma Trial in Beijing (Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous
Not yet recruiting
- Recurrent Glioblastoma
- Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes.
-
Beijing, Beijing, ChinaBeijing Tiantan Hospital
Oct 10, 2022
Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited Trial in Zhengzhou (ThisCART19A, Fludarabine Pill, Cyclophosphamide)
Not yet recruiting
- Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
- ThisCART19A
- +3 more
-
Zhengzhou, Henan, ChinaHenan cancer hospital
Nov 28, 2022
Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma Trial in Taiyuan (CAR-T Autologous T cell injection)
Recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- CAR-T Autologous T cell injection
-
Taiyuan, Shanxi, ChinaShanxi Bethune Hospital
Dec 2, 2022
B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- B Lineage Lymphoblastic Lymphoma
- Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
- Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Jan 25, 2023
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022
Not yet recruiting
- Cancer
- Relapsed/Refractory Large B-cell Lymphoma (LBCL)
- Fludarabine (30 mg/m^2)
- +2 more
- (no location specified)
Jul 25, 2023
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto
Not yet recruiting
- Multiple Sclerosis
- +2 more
- KYV-101 anti-CD19 CAR-T cell therapy
- Standard lymphodepletion regimen
-
Palo Alto, CaliforniaStanford Multiple Sclerosis Center
Nov 13, 2023
Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,
Recruiting
- Lupus Nephritis
- +2 more
- KYV-101 anti-CD19 CAR-T cell therapy
- Standard lymphodepletion regimen
-
Denver, Colorado
- +1 more
Jul 7, 2023
Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,
Not yet recruiting
- Kidney Transplant
- +2 more
- Cyclophosphamide
- +3 more
-
Boston, Massachusetts
- +2 more
Sep 20, 2023
B Acute Lymphoblastic Leukemia Trial in Duarte (drug, procedure, other)
Not yet recruiting
- B Acute Lymphoblastic Leukemia
- Autologous Anti-CD19 CAR-expressing T Lymphocytes
- +6 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 30, 2023
Head Neck Cancer, Relapse, Recurrent Trial in Chapel Hill (Cyclophosphamide, Fludarabine, Cell Therapy)
Not yet recruiting
- Head and Neck Cancer
- +3 more
- Cyclophosphamide
- +2 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Oct 18, 2023
Acute Myeloid Leukemia (AML), B-cell Non-Hodgkin's Lymphoma (B-NHL), Multiple Myeloma (MM) Trial in Shanghai (Autologous CAR-T
Recruiting
- Acute Myeloid Leukemia (AML)
- +4 more
- Autologous CAR-T cells
- +2 more
-
Shanghai, Shanghai, ChinaShanghai Pudong Hospital, Fudan University Affiliated Pudong Med
Aug 22, 2022
AML, B-ALL, T-ALL Trial in Memphis (CD123-CAR T, Cyclophosphamide, Fludarabine)
Recruiting
- AML
- +4 more
- CD123-CAR T
- +4 more
-
Memphis, Tennessee
- +1 more
May 10, 2022
Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma Trial in Memphis (Fludarabine, Cyclophosphamide, MESNA)
Recruiting
- Pediatric Solid Tumor
- +15 more
- Fludarabine
- +3 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Jun 30, 2022
B Cell Non-Hodgkin's Lymphoma Trial in Duarte (CD19/CD20-directed CAR-T cells)
Recruiting
- B Cell Non-Hodgkin's Lymphoma
- CD19/CD20-directed CAR-T cells
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 10, 2022
Malignant Tumor, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the Leptomeninges Trial in Duarte
Recruiting
- Malignant Neoplasm
- +4 more
- Chimeric Antigen Receptor T-Cell Therapy
-
Duarte, CaliforniaCity of Hope Medical Center
Sep 14, 2022
Neuroblastoma Trial in Houston (GINAKIT Cells, Cyclophosphamide, Fludarabine)
Active, not recruiting
- Neuroblastoma
- GINAKIT Cells
- +2 more
-
Houston, TexasTexas Children's Hospital
Jan 18, 2023
DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- +6 more
- Axicabtagene Ciloleucel
- +10 more
- (no location specified)
Jan 13, 2023
Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +8 more
- Cyclophosphamide
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 30, 2022
Glioblastoma Trial in Gainesville (Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells)
Not yet recruiting
- Glioblastoma
- Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
-
Gainesville, FloridaUniversity of Florida Health
Jul 29, 2022
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Trial (C-CAR066)
Not yet recruiting
- Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
- (no location specified)
Mar 23, 2023
High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma, Recurrent B-Cell Non-Hodgkin
Not yet recruiting
- High Grade B-Cell Non-Hodgkin's Lymphoma
- +3 more
- Anti-CD19-CAR CMV-specific T-lymphocytes
- +9 more
-
Duarte, CaliforniaCity of Hope Medical Center
Apr 5, 2023